Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Lymphoma, Non-Hodgkin

abstract

  • These data demonstrate that epratuzumab has a good safety profile and exerts antitumor activity in aggressive non-Hodgkin's lymphoma at doses of > or =240 mg/m2, thus warranting further evaluation in this clinical setting.

publication date

  • August 15, 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-04-0294

PubMed ID

  • 15328168

Additional Document Info

start page

  • 5327

end page

  • 34

volume

  • 10

number

  • 16